Acasti Pharma

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Everett Jolly.

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects. The First Subject, First Dose was administered on September 13th. This PK study is the next step in the proposed 505(b)(2) regulatory pathway for GTX-102 and is expected to be completed with top line results reported before year end.

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Acasti Pharma Inc. (NASDAQ:ACST ) Q1 2023 Earnings Conference Call August 11, 2022 1:00 PM ET Company Participants Robert Blum - Lytham Partners, Investor Relations Jan D'Alvise - President & Chief Executive Officer Brian Ford - Chief Financial Officer Pierre Lemieux - Chief Operating & Scientific Officer Prashant Kohli - Vice President, Commercial Operations Conference Call Participants Leland Gershell - Oppenheimer Operator Good day, and welcome to the Acasti Pharma's First Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in listen-only mode.

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call Transcript

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and novel drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Sever Copley. Copley began the interview by asking about one of the Company's lead clinical assets, GTX-104, targeting underserved orphan diseases. D'Alvise elaborated that GTX-104 is a novel...

Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced the annual grant of performance stock options to its employees and executives.

Acasti Pharma Announces Annual Grants of Performance Stock Options

Acasti Pharma, Inc. (NASDAQ:ACST ) Q4 2022 Earnings Conference Call June 21, 2022 1:00 PM ET Company Participants Robert Blum - Investor Relations Jan D'Alvise - President and Chief Executive Officer Brian Ford - Chief Financial Officer Monique Champagne - Vice President, Clinical Affairs Conference Call Participants Leland Gershell - Oppenheimer Operator Good day, and welcome to the Acasti Pharma Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call. All participants will be in listen-only mode.

Acasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call Transcript

Company to Host Conference Call Today at 1:00pm ET

Acasti Pharma Reports Fiscal Year 2022 Operational Results

Call to be held on Tuesday, June 21st at 1:00 PM Eastern Time Call to be held on Tuesday, June 21st at 1:00 PM Eastern Time

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

LAVAL, QC , May 23, 2022 /PRNewswire/ -- Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) ("Acasti"; the "Company"), a late-stage specialty pharmaceutical company with drug delivery technologies and drug candidates addressing rare and orphan diseases, has retained one of the industry's leading investor relations firms, Lytham Partners, LLC, to lead a strategic investor relations and shareholder communication program. For more than 20 years, Lytham Partners has created a highly diverse network of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications.

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Acasti Pharma Inc's (NASDAQ: ACST) pharmacokinetic (PK) bridging study with IV GTX-104, its lead drug candidate for Subarachnoid Hemorrhage (SAH), met all its planned study endpoints.  The study's primary objective was to evaluate the relative bioavailability of IV GTX-104.

Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine

Evoke Pharma

Guardforce AI Co Ltd

Ricebran Technologies

Penny stocks to watch under $1 today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch Under $1 This Week

Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present at the Spring Into Action- Best Ideas Investor Conference, which is being held virtually May 16-20, 2022. Ms. D'Alvise is scheduled to present on Wednesday, May 18, 2022 at 4:00 p.m.

Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18th

LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present at the Spring Into Action- Best Ideas Investor Conference, which is being held virtually May 16-20, 2022. Ms. D'Alvise is scheduled to present on Monday, May 16, 2022 at 1:30 p.m.

Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial Operations of Acasti Pharma will be presenting at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022 at 4:30 pm ET.

Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors.

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

LAVAL, Québec, March 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the following patent notifications and awards relating to the Company's three lead drug candidates:

Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D'Alvise, President and Chief Executive Officer of Acasti Pharma will be presenting at the 32nd Annual Oppenheimer Healthcare conference being held virtually March 15-17, 2022.

Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

CEO Jan D'Alvise participates in educational interviews regarding rare diseases, including subarachnoid hemorrhage, ataxia-telangiectasia and postherpetic neuralgia CEO Jan D'Alvise participates in educational interviews regarding rare diseases, including subarachnoid hemorrhage, ataxia-telangiectasia and postherpetic neuralgia

Acasti Pharma Celebrates Rare Disease Day

Phoenix, Arizona--(Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's background and current projects. "Acasti is a specialty Pharma company," explained D'Alvise. "We have developed a range of...

Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first half of calendar 2022; GTX-102 and GTX-101 progressing on schedule

News for Acasti Pharma Stock (ACST)